Additional Supporting Information may be found in the online version of this article.


Supplemental Figure 1. qRT-PCR validation of the microarray results

Gene expression of selected targets in Sirt6-/- hepatocytes from microarray data in comparison to qRT-PCR. Data are referenced to corresponding Sirt6+/+ hepatocytes. (A) shows the upregulated and (B) downregulated genes based on the microarray analyses results. (C) Corresponding correlation plot indicating a high concordance between both methods. (Pearson correlation r=0.85; P-value =<0.001)


Supplemental Figure 2. Functional networks by Ingenuity Pathway Analysis Software

Functional networks associated with SIRT6 signature were determined using Ingenuity Pathway Analyses Software.


Supplemental Figure 3. SIRT6 signature in other cancers

(A) SIRT6 signature and clinical outcome of cancer patients from different types of cancer; integrative meta-analysis of genomic data from 40 primary tumors using the Oncomine Microarray database. Data are presented as the mean odds ratio ± SD with P < 0.0001. (B) Number of studies with overexpression of SIRT6 signature. The table shows No. of studies in reference to corresponding clinic-pathological features, Threshold (odds ratio): 2.0, Threshold (p-Value): <0.0001.

hep26413-sup-0004-supptab1.doc1233KSupplemental Table 1. Sirt6 gene expression signature.
hep26413-sup-0005-supptab2.doc180KSupplemental Table 2. Patients at risk.
hep26413-sup-0006-supptab3.doc45KSupplemental Table 3. Top Gene Sets enriched for SIRT6 signalling was identified by the GSEA Microarray tool.
hep26413-sup-0007-supptab4.doc31KSupplemental Table 4. Primer sequences.
hep26413-sup-0008-suppinfo.doc29KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.